中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
1期
17-19
,共3页
慢性肺源性心脏病%肺动脉高压%Rho激酶抑制剂
慢性肺源性心髒病%肺動脈高壓%Rho激酶抑製劑
만성폐원성심장병%폐동맥고압%Rho격매억제제
Chronic pulmonary heart disease%Pulmonary hypertension%Rho kinase inhibitors
目的 观察Rho激酶抑制剂(法舒地尔)对慢性肺源性心脏病患者肺动脉高压的影响,并探讨其作用机制.方法 将60例慢性肺源性心脏病患者随机分为治疗组和对照组各30例,治疗组在常规治疗基础上加用法舒地尔注射液,对照组给予常规治疗.结果 两组患者治疗后与治疗前肺动脉收缩压(SPAP)、肺动脉平均压(MPAP)比较均有显著下降,差异有统计学意义(P＜0.01),治疗后两组SPAP、MPAP比较差异有统计学意义(P＜0.05).结论 Rho激酶抑制剂(法舒地尔)可明显降低慢性肺源性心脏病患者肺动脉高压,改善肺血管重构.对慢性肺源性心脏病患者的治疗具有积极意义.
目的 觀察Rho激酶抑製劑(法舒地爾)對慢性肺源性心髒病患者肺動脈高壓的影響,併探討其作用機製.方法 將60例慢性肺源性心髒病患者隨機分為治療組和對照組各30例,治療組在常規治療基礎上加用法舒地爾註射液,對照組給予常規治療.結果 兩組患者治療後與治療前肺動脈收縮壓(SPAP)、肺動脈平均壓(MPAP)比較均有顯著下降,差異有統計學意義(P＜0.01),治療後兩組SPAP、MPAP比較差異有統計學意義(P＜0.05).結論 Rho激酶抑製劑(法舒地爾)可明顯降低慢性肺源性心髒病患者肺動脈高壓,改善肺血管重構.對慢性肺源性心髒病患者的治療具有積極意義.
목적 관찰Rho격매억제제(법서지이)대만성폐원성심장병환자폐동맥고압적영향,병탐토기작용궤제.방법 장60례만성폐원성심장병환자수궤분위치료조화대조조각30례,치료조재상규치료기출상가용법서지이주사액,대조조급여상규치료.결과 량조환자치료후여치료전폐동맥수축압(SPAP)、폐동맥평균압(MPAP)비교균유현저하강,차이유통계학의의(P＜0.01),치료후량조SPAP、MPAP비교차이유통계학의의(P＜0.05).결론 Rho격매억제제(법서지이)가명현강저만성폐원성심장병환자폐동맥고압,개선폐혈관중구.대만성폐원성심장병환자적치료구유적겁의의.
Objective To observe the effect of Rho kinase inhibitor (fasudil) on pulmonary hypertension patients with chronic pulmonary heart disease,and investigate its mechanism.Methods Sixty patients with chronic pulmonary heart disease were randomly divided into treatment group and control group,the patients in treatment group were given fasudit injection based on regular treatment,the patients in the control group were given routine treatment.Results After treatment,compared with before treatment,SPAP and MPAP were significantly decreased of the two groups,the differences were statistically significant (P ＜ 0.01).After treatment,differences of SPAP,MPAP between the two groups were significant (P ＜ 0.05).Conclusions Rho kinase inhibitor (fasudil) can significantly reduce pulmonary hypertension of chronic pulmonary heart disease,ameliorate pulmonary vascular remodeling,and has positive significance for the treatment of patients with chronic pulmonary heart disease.
